How to access Cuvitru for primary immunodeficiency from the UAE: 2026 pathway via SSMC, CCAD, and Tawam allergy-immunology | Reserve Meds

*Clinically reviewed by Mohammad Ali, MD (US-trained physician, Chief AI Officer, Reserve Meds). Last reviewed 2026-05-20.

The UAE manages PI patients through allergy-immunology services at SSMC, CCAD, Tawam Hospital, Burjeel Medical City, American Hospital Dubai, and Mediclinic City. IVIG infrastructure is established. The 2026 question is whether selected adults and paediatric patients aged 2 and older convert to weekly self-administered SC Cuvitru and how to source it under EDE.

Why Cuvitru, why now

Cuvitru (immune globulin subcutaneous, human - klhw) is a 20 percent subcutaneous immune globulin (SCIG) preparation manufactured by Takeda. FDA approval was granted in September 2016 for the treatment of primary humoral immunodeficiency (PI) in adults and paediatric patients aged 2 years and older, including congenital agammaglobulinemia, common variable immunodeficiency (CVID), X-linked agammaglobulinemia, Wiskott-Aldrich syndrome, and severe combined immunodeficiency. The 20 percent concentration supports weekly home self-administration with smaller infusion volumes than 10 percent SCIG products.

The 2026 question for a UAE PI patient already on IVIG is whether to convert to weekly Cuvitru for steadier IgG troughs, reduced wear-off, less infusion-chair dependency, or to address poor venous access. The UAE has multi-emirate allergy-immunology depth: Sheikh Shakhbout Medical City (SSMC), Cleveland Clinic Abu Dhabi (CCAD), Tawam Hospital, Burjeel Medical City, Sheikh Khalifa Medical City (SKMC), American Hospital Dubai, Mediclinic City Hospital, King's College Hospital Dubai, and Al Jalila Children's Specialty Hospital all maintain established PI services. Reserve Meds does not promote one IgG product over another. Alternatives include Hyqvia (hyaluronidase-facilitated SC), Hizentra, Octagam, Gammagard, Privigen, and others.

What Cuvitru is, in plain language

Cuvitru is a clear-to-slightly-opalescent 20 percent immune globulin solution prepared from screened US plasma donors with multiple viral inactivation and removal steps. It is injected under the skin at the abdomen or thigh using a small subcutaneous needle and a portable infusion pump. After clinic-supervised training (typically two to three sessions), the patient or caregiver self-administers at home, usually once weekly. Each infusion takes 60 to 90 minutes depending on dose and number of sites. Steady-state IgG levels are reached after several cycles, typically by week 8 to 12, with flatter and higher troughs than the IVIG sawtooth pattern.

Access pathway in the UAE

The Emirates Drug Establishment (EDE), formed in 2024 by consolidating the federal medicine regulatory mandate previously held by the Ministry of Health and Prevention (MOHAP), oversees federal-level medicine registration, import licensing, and pharmacovigilance for the entire UAE. The Department of Health Abu Dhabi (DoH Abu Dhabi) governs healthcare facility licensing in Abu Dhabi; the Dubai Health Authority (DHA) covers Dubai; and the Ministry of Health and Prevention covers the Northern Emirates. Cuvitru is not currently EDE-registered. Access therefore runs through an EDE-approved named-patient personal-import authorisation, with the relevant emirate-level health authority acknowledgment, filed by the treating allergist-immunologist at SSMC, CCAD, Tawam, SKMC, Burjeel Medical City, American Hospital Dubai, Mediclinic City, King's College, or one of the other licensed centres.

The treating physician submits a named-patient import application detailing the PI diagnosis, the rationale for SCIG conversion, prior IVIG experience, and the requested dose and shipment quantity. EDE reviews and issues an import authorisation per shipment. Reserve Meds sources Cuvitru from a US DSCSA-compliant specialty wholesaler, prepares the manufacturer pedigree, and ships under validated cold chain (2 to 8 degrees Celsius) to Abu Dhabi or Dubai International Airport for clearance.

Eligibility at a UAE allergy-immunology clinic

Cuvitru eligibility requires a confirmed PI diagnosis with documented IgG deficiency (often subclass deficiency), impaired specific antibody response (vaccine challenge with pneumococcal polysaccharide or tetanus antigens), or genetic confirmation of a defined PI syndrome. The treating immunologist documents baseline IgG, IgA, IgM, specific antibody responses, infection history, and confirms self-administration capability. An IgG trough goal is set, typically 7 to 12 g/L depending on syndrome and infection burden. Paediatric cases age 2 and older are eligible and are typically managed at Tawam, CCAD, SSMC, or Al Jalila Children's Specialty Hospital.

Documentation required

The patient and physician should be prepared to provide: a current Emirates ID or passport; the diagnostic immunology workup including immunoglobulin panels, vaccine-challenge responses, and any genetic confirmation; documentation of infection history; prior IVIG infusion records and tolerability issues; the treating immunologist's prescription on hospital letterhead; a clinical justification letter detailing the SCIG rationale; the EDE named-patient import application; the emirate-level health authority acknowledgment (DoH Abu Dhabi, DHA, or MOHAP); and evidence of payment capacity or insurance pre-authorisation. Reserve Meds prepares the US export documentation, manufacturer pedigree, and customs packet.

Costs and funding considerations

The annual cost band for Cuvitru in the UAE is USD 75,000 to 110,000 per patient (AED 275,000 to 405,000), weight-and-dose dependent. Typical maintenance dosing is 100 to 200 mg/kg per week. Thiqa coverage for Emirati nationals may apply under the PI rare-disease provision case-by-case. Daman Enhanced, Daman Premier, DHA Saada, AXA Gulf, Allianz, MetLife, BUPA Arabia, NEXtCARE, and Oman Insurance plans commonly cover IVIG and SCIG with pre-authorisation when PI is confirmed. Reserve Meds will help structure the insurer or government-payor submission with the treating physician.

Typical timeline

Weeks 0 to 2: clinical eligibility review, EDE filing, prescription preparation, training arrangement. Weeks 2 to 4: shipment arrival at Abu Dhabi or Dubai International Airport, clinic-supervised SC training (two to three sessions), home-environment setup. Weeks 4 to 16: weekly SC infusions at home with patient logs; IgG trough at week 12. Months 6 and 12: full reassessment, infection-event log review, dose adjustment as needed.

When Cuvitru is the wrong drug

Patients with good venous access and no desire to self-inject are usually better served by continuing IVIG. Patients unable to reliably self-administer (cognitive impairment, no caregiver) are safer on IVIG with hospital-supervised infusion. Patients who cannot maintain a weekly schedule may prefer Hyqvia (monthly SC with hyaluronidase). IgA-deficient patients with anti-IgA antibodies require additional caution and discussion of low-IgA product selection with the treating immunologist. Reserve Meds does not promote one IgG product over another.

Frequently asked questions

• Is the pathway legal in the UAE? Yes. It operates under EDE named-patient personal-import authorisation with emirate-level health authority acknowledgment under federal UAE medicines law.
• Will Thiqa, DHA Saada, or my insurance cover Cuvitru? Emirati nationals may secure Thiqa or DHA Saada rare-disease support case-by-case; private insurance pre-authorisation is generally available where PI is confirmed.
• How is Cuvitru shipped? Validated cold chain (2 to 8 degrees Celsius) with temperature-monitored containers from a US DSCSA-compliant specialty wholesaler to Abu Dhabi or Dubai International Airport.
• Can my child use Cuvitru? Cuvitru is FDA-approved for paediatric patients aged 2 and older; paediatric cases are typically managed at Tawam, CCAD, SSMC, or Al Jalila Children's Specialty Hospital.
• What if Cuvitru is in short supply at the US level? Reserve Meds will inform you upfront and decline rather than promise a timeline we cannot deliver. We do not source from unverified channels.

Closing

Reserve Meds runs the Cuvitru supply file from the SSMC, CCAD, Tawam, SKMC, Burjeel Medical City, American Hospital Dubai, Mediclinic City, or other UAE allergy-immunology referral through EDE named-patient authorisation and delivered cold-chain supply. Clinical decisions remain with your treating allergist-immunologist. To open a case, start your file in the patient portal or message us on WhatsApp; we will return a delivered quote within 24 hours.

Composite case examples; no individual patient is depicted. This content is for general information and does not constitute medical advice. Reserve Meds is a US-based concierge